CA
CAI.US Caris Life Sciences, Inc. Common Stock
- Market cap
- USD 6.61B
- P/E
- 13.9x
- P/B
- 10.75x
- ROE
- 2.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CAI.US undervalued?
Graham numberCAI.US trades 157.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Caris Life Sciences, Inc. Common Stock fundamental analysis
No fundamental analysis for Caris Life Sciences, Inc. Common Stock yet.
Caris Life Sciences, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Caris Life Sciences, Inc. Common Stock
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular …
Full company profileCaris Life Sciences, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Caris Life Sciences, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 250M | 294M | 348M | 432M | 417M | 294M | 258M | 306M | 412M | 812M | 1.01B |
| Gross Profit | 126M | 137M | 169M | 214M | 201M | 184M | 80.0M | 89.3M | 179M | 539M | 671M |
| Operating Income | 68.1M | 66.0M | 106M | 149M | 130M | 139M | -316M | -320M | -257M | 45.1M | 68.7M |
| EBITDA | 181M | 159M | 224M | 283M | 248M | 254M | -246M | -261M | -183M | 11.4M | 78.0M |
| Net Income | 26.8M | 6.00M | 72.1M | 78.6M | 31.0M | 27.7M | -321M | -341M | -282M | -538M | 18.8M |
| EPS | 1.28 | 0.31 | 3.68 | 3.97 | 1.72 | 1.55 | -1.26 | -1.34 | -7.94 | -3.22 | 0.06 |
| Balance Sheet | |||||||||||
| Total Assets | 1.99B | 2.06B | 2.43B | 3.01B | 2.90B | 2.61B | 717M | 413M | 344M | 1.13B | 1.26B |
| Total Liabilities | 1.53B | 1.60B | 1.87B | 2.31B | 2.21B | 1.91B | 2.42B | 2.56B | 2.84B | 548M | 616M |
| Shareholders' Equity | 460M | 458M | 564M | 701M | 693M | 702M | -1.70B | -2.14B | -2.50B | 577M | 639M |
| Cash & Short-term Investments | 73.7M | 66.1M | 65.5M | 121M | 46.5M | 133M | 410M | 122M | 66.2M | 800M | 767M |
| Total Debt | 1.43B | 1.48B | 1.70B | 2.16B | 2.10B | 1.75B | 271M | 217M | 424M | 379M | 463M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 147M | 129M | 155M | 180M | 254M | 277M | -286M | -276M | -245M | 83.2M | 96.0M |
| Capital Expenditure | 389M | 251M | 502M | 813M | 319M | 219M | 42.3M | 22.3M | 8.44M | 16.3M | 80.3M |
| Free Cash Flow | -242M | -122M | -347M | -633M | -65.1M | 57.6M | -328M | -298M | -254M | 66.9M | 15.7M |
| Ratios | |||||||||||
| ROE | 5.8% | 1.3% | 12.8% | 11.2% | 4.5% | 3.9% | - | - | - | -93.2% | 2.9% |
| ROA | 1.4% | 0.3% | 3.0% | 2.6% | 1.1% | 1.1% | -44.7% | -82.7% | -82.0% | -47.8% | 1.5% |
| Net Profit Margin | 10.7% | 2.0% | 20.7% | 18.2% | 7.4% | 9.4% | -124.1% | -111.5% | -68.4% | -66.2% | 1.9% |
| Debt to Equity | 3.11x | 3.23x | 3.02x | 3.08x | 3.03x | 2.49x | - | - | - | 0.66x | 0.72x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Caris Life Sciences, Inc. Common Stock dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2020 | USD 17.7M | 0.99 | 63.8% |
| 2019 | USD 8.83M | 0.49 | 28.5% |
| 2018 | USD 3.26M | 0.16 | 4.1% |
| 2017 | - | - | - |
| 2016 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Caris Life Sciences, Inc. Common Stock
- Insiders 48.08%
- Institutions 51.92%
- Public & others 0.00%
- Shares outstanding 287M
- Free float 139M
Top funds holding CAI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Contrafund | 4.37M | 1.52% | +7.30% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 4.07M | 1.42% | +0.31% | Sep 2026 |
| American Funds SMALLCAP World A | 3.01M | 1.05% | +154.80% | Sep 2026 |
| Vanguard Small Cap Index | 2.86M | 1.00% | -2.11% | Sep 2026 |
| JPMorgan Mid Cap Growth I | 2.09M | 0.73% | -1.56% | Sep 2026 |
| Worldwide Healthcare Ord | 1.99M | 0.70% | 0.00% | Jul 2026 |
| T. Rowe Price New Horizons | 1.89M | 0.66% | +37.98% | Sep 2026 |
| Fidelity Select Health Care | 1.89M | 0.66% | -0.12% | Aug 2026 |
| Strategic Advisers Fidelity US TtlStk | 1.83M | 0.64% | +8.87% | Sep 2026 |
| Fidelity VIP Mid Cap Initial | 1.79M | 0.63% | 0.00% | Sep 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 1.59M | 0.56% | -5.35% | Sep 2026 |
| Fidelity VIP Contrafund Initial | 1.42M | 0.50% | +1.67% | Sep 2026 |
| Fidelity Advisor New Insights I | 1.31M | 0.46% | +1.72% | Sep 2026 |
| American Funds New Economy A | 1.11M | 0.39% | 0.00% | Sep 2026 |
| Fidelity Select Medical Tech and Devcs | 1.00M | 0.35% | -19.65% | Sep 2026 |
| iShares Biotechnology ETF | 990K | 0.35% | -0.19% | Oct 2026 |
| Fidelity Small Cap Growth | 961K | 0.34% | 0.00% | Aug 2026 |
| Fidelity Contrafund K6 | 925K | 0.32% | +7.31% | Sep 2026 |
| Fidelity Tactical High Income Sr F8 | 922K | 0.32% | -19.82% | Jun 2026 |
| Fidelity Growth Company Fund | 891K | 0.31% | 0.00% | Aug 2026 |
Top institutions holding CAI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 30.9M | 10.95% | +0.45% | Jun 2026 |
| J. H. Whitney Equity Partners VI, LLC | 11.3M | 3.98% | -38.34% | Jun 2026 |
| Coatue Management LLC | 9.82M | 3.48% | 0.00% | Jun 2026 |
| BRAIDWELL LP | 8.26M | 2.92% | +3.08% | Jun 2026 |
| Sixth Street Partners Management Company, L.P. | 7.33M | 2.59% | -49.07% | Jun 2026 |
| PointState Capital LP | 6.83M | 2.42% | -7.22% | Jun 2026 |
| JPMorgan Chase & Co | 6.56M | 2.32% | +89.54% | Jun 2026 |
| BlackRock Inc | 5.54M | 1.96% | +13.99% | Jun 2026 |
| T. Rowe Price Investment Management,Inc. | 5.08M | 1.80% | -9.11% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 4.84M | 1.71% | +28.89% | Jun 2026 |
| Vanguard Capital Management, LLC | 4.28M | 1.52% | +28.57% | Jun 2026 |
| Neuberger Berman Group LLC | 3.59M | 1.27% | +0.01% | Jun 2026 |
| Orbimed Advisors LLC | 2.81M | 0.99% | 0.00% | Jun 2026 |
| BNP Paribas Arbitrage, SA | 2.37M | 0.84% | +46.83% | Jun 2026 |
| Millennium Management LLC | 2.20M | 0.78% | +44.18% | Jun 2026 |
| Mak Capital One LLC | 1.94M | 0.69% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.94M | 0.69% | +79.31% | Jun 2026 |
| Duquesne Family Office LLC | 1.89M | 0.67% | 0.00% | Jun 2026 |
| ClearBridge Advisors, LLC | 1.60M | 0.56% | +2.84% | Jun 2026 |
| Fidelity International Ltd | 1.55M | 0.55% | +0.18% | Jun 2026 |
Caris Life Sciences, Inc. Common Stock company profile
- Company name
- Caris Life Sciences, Inc. Common Stock
- Ticker
- CAI.US
- Exchange
- USA Stocks
- Listed since
- Jun 18, 2025
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Employees
- 1,846
- Fiscal year end
- December
- Address
- 750 West John Carpenter Freeway, Irving, TX, United States, 75039
- Phone
- 866 771 8946
- Website
- carislifesciences.com
About Caris Life Sciences, Inc. Common Stock
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.
Caris Life Sciences, Inc. Common Stock management
10- Dr. David Dean Halbert M.D.Chairman, CEO & Founder · born 1956
- Mr. Brian J. Brille J.D.Executive Vice Chairman & Executive VP · born 1961
- Dr. David Spetzler M.B.A., M.S., Ph.D.President · born 1977
- Mr. J. Russel DentonSenior VP, General Counsel & Secretary · born 1984
- Mr. Luke PowerSenior VP, CFO & Chief Accounting Officer · born 1982
- Mr. Jon Mark HarmonSenior VP & Chief Operations Officer
- Dr. Milan Radovich Ph.D.Senior VP & Chief Scientific Officer
- Mr. Jeremy O'BrienSenior VP of HR & Chief Compliance Officer
- Mr. Narendra ChokshiSenior Vice President of Corporate Development
- Ms. Stephanie ThomasExecutive VP & Chief of Staff at Office of the CEO